Literature DB >> 32179967

Analysis of the women with the AMH concentrations below the limit of reference range but with the ideal number of retrieved oocytes.

Wenbin Wu1, Xingling Wang2, Yushan Li2, Yuchao Zhang2.   

Abstract

PURPOSE: Serum anti-Mullerian hormone (AMH) shows a strong positive correlation to the number of oocytes retrieved but the patients undergoing assisted reproductive technology (ART) with lower AMH concentrations also could retrieve an ideal number of oocytes sometimes. The aim of the current study was to assess the performance of this population.
METHODS: This retrospective study included a total of 44 in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment cycles as test group, in which their AMH levels were below the limit of reference range but more than 7 eggs were retrieved, and 103 control cases enrolled from May 2016 to December 2018 after matched with the same range of age from 24 to 38 years old and the same number range of retrieved oocytes from 7 to 18 and chosen randomly according to clinical ovarian stimulation protocols by the ratio of 3:7. Several parameters, which include age, basal endocrine status, number of oocytes, the maturation rate of eggs, 2PN fertilization rate, 3PN rate, total fertilization rate, cleavage rate, 8-cell embryo rate of D3 and the utilization rate of embryo, were compared and evaluated between two groups by Wilcoxon rank-sum test and t test for two independent samples.
RESULTS: Although the same age range from 24 to 38 years and the same retrieval eggs from 7 to 18, compared with the control group, the test group showed less number of oocytes collected (9.455 vs 10.767, p = 0.016), younger ages (28.36 vs 32.59, p = 0.000), and higher FSH of basal endocrine status (9.783 vs 7.338, p = 0.021). Between the two groups, there were no significant differences in parameters such as the mature eggs (7.05 vs 7.92, p = 0.079), the mature oocyte rate (74.189% vs 73.916%, p = 0.924), the number of 2PNs (5.36 vs 5.91, p = 0.236), 2PN rate (73.678% vs 75.125%, p = 0.769), the number of 3PNs (0.39 vs 0.50, p = 0.773), 3PN rate (5.104% vs 5.592%, p = 0.697), number of total fertilizations (6.77 vs 7.35, p = 0.241), total fertilization rate (96.461% vs 93.166%, p = 0.332), cleavage rate (82.003% vs 81.382%, p = 0.673), the number of 8-cells on D3 (1.59 vs 1.91, p = 0.227), the rate of 8-cell on D3 (36.259% vs 41.084%, p = 0.551) and the utilization rate of embryo (62.853% vs 61.824%, p = 0.806).
CONCLUSIONS: These findings indicate that there are no significant differences in the maturation of oocytes and the embryo quality for the women with low AMH level and ideal retrieval eggs but they should undergo IVF treatment and achieve successful pregnancy as soon as possible due to the higher basal FSH, the relatively fewer number of retrieval eggs and the possibility of coming diminished ovarian reserve (DOR) or poor respond (PR) despite their younger ages.

Entities:  

Keywords:  Anti-Müllerian hormone; Assisted reproductive technology; Controlled ovarian stimulation; Embryo quality

Mesh:

Substances:

Year:  2020        PMID: 32179967     DOI: 10.1007/s00404-020-05491-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  17 in total

1.  Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles.

Authors:  T Ebner; M Sommergruber; M Moser; O Shebl; E Schreier-Lechner; G Tews
Journal:  Hum Reprod       Date:  2006-05-05       Impact factor: 6.918

2.  Specific ranges of anti-Mullerian hormone and antral follicle count correlate to provide a prognostic indicator for IVF outcome.

Authors:  Kevin Keane; Vincius Fernandes Cruzat; Susbin Wagle; Nitin Chaudhary; Philip Newsholme; John Yovich
Journal:  Reprod Biol       Date:  2017-01-26       Impact factor: 2.376

3.  The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos.

Authors:  Kingshuk Majumder; Tarek A Gelbaya; Ian Laing; Luciano G Nardo
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2010-03-11       Impact factor: 2.435

4.  Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.

Authors:  André Hazout; Philippe Bouchard; David B Seifer; P Aussage; Anne Marie Junca; Paul Cohen-Bacrie
Journal:  Fertil Steril       Date:  2004-11       Impact factor: 7.329

5.  Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary.

Authors:  A L Durlinger; M J Gruijters; P Kramer; B Karels; T R Kumar; M M Matzuk; U M Rose; F H de Jong; J T Uilenbroek; J A Grootegoed; A P Themmen
Journal:  Endocrinology       Date:  2001-11       Impact factor: 4.736

Review 6.  Assessing ovarian response: antral follicle count versus anti-Müllerian hormone.

Authors:  Richard Fleming; David B Seifer; John L Frattarelli; Jane Ruman
Journal:  Reprod Biomed Online       Date:  2015-07-03       Impact factor: 3.828

7.  Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.

Authors:  E Tsakos; A Tolikas; Angelos Daniilidis; B Asimakopoulos
Journal:  Arch Gynecol Obstet       Date:  2014-07-08       Impact factor: 2.344

Review 8.  Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).

Authors:  A La Marca; G Sighinolfi; D Radi; C Argento; E Baraldi; A Carducci Artenisio; G Stabile; A Volpe
Journal:  Hum Reprod Update       Date:  2009-09-30       Impact factor: 15.610

9.  The effect of serum and follicular fluid anti-Mullerian hormone level on the number of oocytes retrieved and rate of fertilization and clinical pregnancy.

Authors:  Seda Eymen Bolat; Safak Ozdemirci; Taner Kasapoglu; Bulent Duran; Levent Goktas; Ertugrul Karahanoglu
Journal:  North Clin Istanb       Date:  2016-11-25

Review 10.  The physiology and clinical utility of anti-Mullerian hormone in women.

Authors:  Didier Dewailly; Claus Yding Andersen; Adam Balen; Frank Broekmans; Nafi Dilaver; Renato Fanchin; Georg Griesinger; Tom W Kelsey; Antonio La Marca; Cornelius Lambalk; Helen Mason; Scott M Nelson; Jenny A Visser; W Hamish Wallace; Richard A Anderson
Journal:  Hum Reprod Update       Date:  2014-01-14       Impact factor: 15.610

View more
  1 in total

1.  Prediction of Fertilization Disorders in the In Vitro Fertilization/Intracytoplasmic Sperm Injection: A Retrospective Study of 106,728 Treatment Cycles.

Authors:  Tian Tian; Lixue Chen; Rui Yang; Xiaoyu Long; Qin Li; Yongxiu Hao; Fei Kong; Rong Li; Yuanyuan Wang; Jie Qiao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-20       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.